Oxford biotech developing RNA-based therapies for chronic liver disease using donated human livers.
| Date | Round | Amount |
|---|---|---|
| Oct 2022 | Series A Irish-founded, Oxford-based Ochre Bio raised a $30m Series A from Khosla Ventures and others to develop liver disease treatments. | $30M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.